These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32429380)

  • 1. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
    Parisi A; Cortellini A; Cannita K; Venditti O; Camarda F; Calegari MA; Salvatore L; Tortora G; Rossini D; Germani MM; Boccaccino A; Dell'Aquila E; Fulgenzi C; Santini D; Tursi M; Tinari N; Marino PD; Lombardi P; Keränen SR; Álvaro MH; Zurlo IV; Corsi DC; Emiliani A; Zanaletti N; Troiani T; Vitale P; Giampieri R; Merloni F; Occhipinti MA; Marchetti P; Roberto M; Mazzuca F; Ghidini M; Indini A; Garajova I; Zoratto F; Monache SD; Porzio G; Ficorella C
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Induction Management in Patients With Left-Sided
    Parisi A; Cortellini A; Venditti O; Filippi R; Salvatore L; Tortora G; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Fulgenzi C; Lombardi P; Roselló Keränen S; Depetris I; Giampieri R; Morelli C; Di Marino P; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Patruno L; D'Orazio C; Ficorella C; Ferri C; Porzio G
    Front Oncol; 2021; 11():712053. PubMed ID: 34778029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type
    Jiang W; Yu Q; Ning R; Zhao W; Wei C
    Onco Targets Ther; 2018; 11():4271-4281. PubMed ID: 30100734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
    Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
    Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
    Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
    Antonetti P; Fargnoli MC; Porzio G; Salvatore L; Filippi R; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Dell'Aquila E; Lombardi P; Keränen SR; Depetris I; Giampieri R; Morelli C; De Tursi M; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Cortellini A; Pensieri MV; Ficorella C; Ferri C; Parisi A
    Support Care Cancer; 2022 Mar; 30(3):2455-2465. PubMed ID: 34779921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis.
    Wang H; Ma B; Gao P; Song Y; Xu Q; Hu Y; Zhang C; Wang Z
    Onco Targets Ther; 2016; 9():5405-16. PubMed ID: 27621654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
    Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice.
    Buchler T; Kiss I; Hornova J; Fiala O; Wiesnerova M; Svoboda M; Silar J; Kopeckova K; Poprach A; Finek J; Petruzelka L; Melichar B
    Target Oncol; 2020 Apr; 15(2):193-201. PubMed ID: 32052341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
    Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
    J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
    Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
    J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy.
    Cai C; Luo Q; Liu Y; Peng Y; Zhang X; Jiang Z; Feng Z; Qi Y; Gao Y; Liu Y; Liu P; Chen Y; Guo C; Shen H; Zeng S; Han Y
    Front Pharmacol; 2022; 13():1015510. PubMed ID: 36249804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.
    Yildirim ME; Karadurmuş N; Ökten İN; Türk HM; Urakçı Z; Arslan Ç; Çelik S; Dane F; Şendur MAN; Bilir C; Karabulut B; Cicin İ; Çubukçu E; Karaca M; Ozcelik M; Artaç M; Tanrikulu E; Alacacioglu A; Açıkgöz Ö; Öven B; Geredeli Ç; Çil T; Harputluoğlu H; Kefeli U; Bozkurt O; Tural D; Sakin A; Yalçın Ş; Gumus M
    J Oncol Pharm Pract; 2024 Apr; ():10781552241241004. PubMed ID: 38613329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study.
    Grassadonia A; Di Marino P; Ficorella C; Cortellini A; Cannita K; Parisi A; Gamucci T; Zoratto F; Vici P; Barba M; Porreca E; Neri M; Veronese A; Natoli C; De Tursi M; Tinari N
    J Cancer; 2019; 10(24):5926-5934. PubMed ID: 31762802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with
    Tsai HL; Huang CW; Ma CJ; Su WC; Chang TK; Chen PJ; Yeh YS; Wang JY
    Transl Cancer Res; 2019 Oct; 8(6):2357-2370. PubMed ID: 35116988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.